Mar­tin Shkre­li to go toe-to-toe with new FTC chair over Dara­prim price spikes

Much ink has been spilled over “Phar­ma Bro” Mar­tin Shkre­li, the en­tre­pre­neur who raised the price of a life­sav­ing an­tipar­a­sitic more than 55-fold overnight and is cur­rent­ly serv­ing a sev­en-year prison sen­tence for se­cu­ri­ties fraud.

But he’s al­so fac­ing an­titrust charges from the FTC and the agency’s new chair Lina Khan, and a court date has fi­nal­ly been set for the case.

Shkre­li has been or­dered to ap­pear in per­son for the an­titrust tri­al on Dec. 14, as Khan looks to bring the ham­mer down on what the FTC al­leges were mo­nop­o­lis­tic prac­tices by Tur­ing Phar­ma­ceu­ti­cals, now Vy­era. Reg­u­la­tors have as­sert­ed that Vy­era at­tempt­ed to buy up most — if not all — sup­ply of the drug that cat­a­pult­ed Shkre­li in­to in­famy, Dara­prim, in or­der to pre­vent gener­ic com­pe­ti­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER